 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > NeoPharm, Inc.
 |
NeoPharm, Inc. |
 |
 |
 |
PROFILE |
 |
NeoPharm develops new drugs to treat various forms of cancer. The company utilizes two technology platforms -- liposome drug delivery and tumor targeting -- to develop its drugs. Its two primary product candidates, liposome encapsulated paclitaxel (LEP) and liposome encapsulated doxorubicin (LED) target solid tumors and breast, blood, and prostate cancers, respectively. NeoPharm's leading tumor-targeting product, IL13-PE38, is designed to attack tumors in kidney and brain cancers. NeoPharm has a worldwide development and licensing agreement with Pharmacia for LEP and LED. Chairman John Kapoor owns more than a quarter of the company.
COMPETITION |
 |
Bristol-Myers Squibb Company (BMY)
Cytoclonal Pharmaceutics Inc. (CYPH)
NaPro BioTherapeutics, Inc. (NPRO)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 3.00
1-Yr. Sales Growth: (72.7)%
Employees: 19
Revenue per employee: $157,894.74
KEY PEOPLE |
 |
James M. Hussey
CEO
Lawrence A. Kenyon
CFO
CONTACT INFO |
 |
150 Field Dr., Ste. 195
Lake Forest, IL 60045
US
Phone: 847-295-8678
Fax: 847-295-8854
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |